Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion

被引:30
|
作者
Harding, Pamela [1 ]
Yang, Xiao-Ping [1 ]
He, Quan [1 ]
LaPointe, Margot C. [1 ]
机构
[1] Henry Ford Hosp, Hypertens & Vasc Res Div, Dept Internal Med, Detroit, MI 48202 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2011年 / 300卷 / 03期
关键词
microsomal prostaglandin E synthase-1; angiotensin II; hypertrophy; MYOCARDIAL-INFARCTION; OXIDATIVE STRESS; MICE LACKING; VENTRICULAR MYOCYTES; PRESSOR-RESPONSE; GENE-EXPRESSION; KNOCKOUT MICE; HYPERTENSION; INHIBITION; RECEPTOR;
D O I
10.1152/ajpheart.00772.2010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Harding P, Yang XP, He Q, LaPointe MC. Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 300: H1053-H1061, 2011. First published December 30, 2010; doi: 10.1152/ajpheart.00772.2010.-Our laboratory previously reported that inducible PGE(2) synthase, mPGES-1, contributes to micromolar production of PGE(2) in neonatal ventricular myocytes in vitro, which stimulates their growth. We therefore hypothesized that mPGES-1 contributes to cardiac hypertrophy following angiotensin II (ANG II) infusion. To test this hypothesis, we used 10-to 12-wk-old mPGES-1 knockout mice (mPGES-1 KO) and C57Bl/6 control mice infused for 8 wk with either 1.4 mg.kg(-1).day(-1) ANG II or vehicle subcutaneously. Blood pressure [systolic blood pressure (SBP)] was measured throughout the study, and cardiac function was assessed by M-mode echocardiography at baseline and at 8 wk of infusion. At the conclusion of the study, immunohistochemistry was used to evaluate collagen fraction, myocyte cross-sectional area (MCSA), and apoptosis. At baseline, there was no difference in SBP between mPGES-1 KO mice and C57BL/6 controls. ANG II infusion increased SBP to similar levels in both strains. In control mice, infusion of ANG II increased MCSA and posterior wall thickness at diastole (PWTd) but had little effect on cardiac function, consistent with compensatory hypertrophy. In contrast, cardiac function was worse in mPGES-1 KO mice after ANG II treatment. Ejection fraction declined from 76.2 +/- 2.7 to 63.3 +/- 3.4% after ANG II, and left ventricular dimension at systole and diastole increased from 1.29 +/- 0.02 to 1.78 +/- 0.15 mm and from 2.57 +/- 0.03 to 2.90 +/- 0.13 mm, respectively. Infusion of ANG II increased both the LV-to-body weight and the mass-to-body weight ratios to a similar extent in both strains. However, PWTd increased by a lesser extent in KO mice, suggesting an impaired hypertrophic response. ANG II infusion increased collagen staining similarly in both strains, but TdT-dUTP nick end labeling staining was greater in mPGES-1 KO mice. Overall, these results are consistent with a beneficial effect for mPGES-1 in the maintenance of cardiac function in ANG II-dependent hypertension.
引用
收藏
页码:H1053 / H1061
页数:9
相关论文
共 50 条
  • [41] Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective
    Yasmen, Nelufar
    Sluter, Madison N. N.
    Li, Lexiao
    Yu, Ying
    Jiang, Jianxiong
    MOLECULAR BRAIN, 2023, 16 (01)
  • [42] Characterization of Microsomal Prostaglandin E Synthase 1 Inhibitors
    Korotkova, Marina
    Jakobsson, Per-Johan
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 114 (01) : 64 - 69
  • [43] Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis
    Lu, D.
    Han, C.
    Wu, T.
    ONCOGENE, 2012, 31 (07) : 842 - 857
  • [44] Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo
    Di Francesco, Luigia
    Bruno, Annalisa
    Ricciotti, Emanuela
    Tacconelli, Stefania
    Dovizio, Melania
    Guillem-Llobat, Paloma
    Alisi, Maria Alessandra
    Garrone, Beatrice
    Coletta, Isabella
    Mangano, Giorgina
    Milanese, Claudio
    FitzGerald, Garret A.
    Patrignani, Paola
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [45] Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells
    Takahashi, R.
    Amano, H.
    Satoh, T.
    Tabata, K.
    Ikeda, M.
    Kitasato, H.
    Akira, S.
    Iwamura, M.
    Majima, M.
    BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (01) : 71 - 77
  • [46] Microsomal Prostaglandin E2 Synthase-1 Deletion Attenuates Isoproterenol-Induced Myocardial Fibrosis in Mice
    Ji, Shuang
    Guo, Rui
    Wang, Jing
    Qian, Lei
    Liu, Min
    Xu, Hu
    Zhang, Jiayang
    Guan, Youfei
    Yang, Guangrui
    Chen, Lihong
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 375 (01) : 40 - 48
  • [47] Microsomal Prostaglandin E Synthase-1 and Endothelial EP4 Receptor Reduces Myocardial Ischemia-reperfusion Injury via Improving Microcirculatory Perfusion
    Zhu, Liyuan
    Xu, Chuansheng
    Hao, Huifeng
    Hu, Sheng
    Wan, Qing
    Wang, Miao
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [48] Microsomal Prostaglandin E Synthase-1 and-2: Emerging Targets in Non-Alcoholic Fatty Liver Disease
    Kotsos, Dimitrios
    Tziomalos, Konstantinos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [49] Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1
    Dong-juan Zhang
    Li-hong Chen
    Ya-hua Zhang
    Guang-rui Yang
    Dou Dou
    Yuan-sheng Gao
    Xiao-yan Zhang
    Xiao-mu Kong
    Pan Zhao
    Dan Pu
    Ming-fen Wei
    Matthew-D Breyer
    You-fei Guan
    Acta Pharmacologica Sinica, 2010, 31 : 1284 - 1292
  • [50] Valproic Acid Suppresses Interleukin-1β-induced Microsomal Prostaglandin E2 Synthase-1 Expression in Chondrocytes Through Upregulation of NAB1
    Zayed, Nadia
    El Mansouri, Fatima Ezzahra
    Chabane, Nadir
    Kapoor, Mohit
    Martel-Pelletier, Johanne
    Benderdour, Mohamed
    Pelletier, Jean-Pierre
    Duval, Nicolas
    Fahmi, Hassan
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (03) : 492 - 502